Informations

For patients with end-stage kidney disease, kidney transplantation represents a life-changing treatment that can restore quality of life and offer a “second chance.” However, transplantation success is only the beginning of a long journey. Lifelong immunosuppressive therapy—while essential for preventing rejection—also exposes recipients to a significant risk: infection.

The concept of synthetic lethality, achieved through PARP inhibitors (PARPi), has ushered in the era of precision therapy for prostate cancer. Clinical studies evaluating PARPi either as monotherapy or in combination with next-generation androgen receptor pathway inhibitors (ARPI), such as PROfound and PROpel, have already produced landmark advances in the treatment of metastatic castration-resistant prostate…

The treatment landscape for muscle-invasive bladder cancer (MIBC) is undergoing profound transformation. Although cisplatin-based neoadjuvant chemotherapy remains the traditional standard of care, the pathological complete response (pCR) rate has long remained at approximately 30%–40%, and a substantial proportion of patients cannot receive cisplatin due to factors such as renal insufficiency. Consequently, more effective preoperative treatment…

At the 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2026), Chinese investigators once again made a strong impact on the international stage. Immunotherapy combined with targeted therapy has become the mainstream treatment paradigm for advanced renal cell carcinoma. However, key clinical questions remain unresolved worldwide, particularly how to optimize…

The 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2026) has successfully concluded. As the premier annual academic event in the field of genitourinary oncology, the meeting brought together leading experts from around the world and showcased numerous cutting-edge studies and breakthroughs with the potential to reshape clinical practice.

The 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2026) was held in San Francisco, USA, from February 26 to 28, showcasing some of the most innovative scientific advances in the field and exploring future directions in the treatment of genitourinary malignancies. In recent years, research and clinical practice in…

The 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) was held in San Francisco, bringing together leading experts from around the world. As one of the most influential academic meetings in genitourinary oncology, the landmark studies presented each year at ASCO GU often directly shape the evolution of clinical practice…